熱門資訊> 正文
INmune和Elevai Labs修改许可协议
2024-07-12 19:12
- Skincare product maker Elevai Labs (NASDAQ:ELAB) announced Friday that the company and cancer drug developer INmune Bio (NASDAQ:INMB) amended a licensing deal reached early this year.
- According to a regulatory filing, the amendment relates to the deal that handed Elevai (ELAB) the global licensing rights to use INmune's (INMB) "EMx" manufacturing technology for ten years.
- While Elevai (ELAB) didn't specify its financial implications, the company said that the amendment covered, among other things, a tech transfer fee payable to INmune (INMB).
- "EMx" technology is designed to efficiently produce current Good Manufacturing Practice ("cGMP")-grade human umbilical cord-derived mesenchymal stromal cells used to create topical cosmetic products.
- Under the initial agreement, Elevai (ELAB) was expected to make a final tech transfer fee within two years in addition to an early deposit due within six months.
More on INmune Bio
- INmune Bio: Promising Phase 2 Trials For Alzheimer's Drug XPro
- INmune Bio: Still A Bargain If Their Alzheimer's Program Reaches Its Inflection
- INmune Bio, Inc. (INMB) Q1 2024 Earnings Call Transcript
- INmune Bio provides update on Alzheimer's candidate XPro
- INmune Bio rises 2%, on $4.5M direct offering
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
